Skip to content
Open access

Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

Sep 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11702 - 11709 · 0 citations · 9 references
Medicine

Abstract

Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D).

Read PDF

Similar papers

Open access Sep 2026

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

This study assessed the real‐world effectiveness and safety of a fixed‐dose combination (FDC) of metformin and empagliflozin in Chinese patients with type 2 diabetes mellitus (T2DM).

Wei-Jian Ke, Ying-Hong Kong, Song-Bo Fu et al. · 0 citations
Open access Oct 2026

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.

Jun-Sung Moon, K. Han, Dong-Lim Kim et al. · 0 citations
Open access Oct 2026

EMPAGLIFLOZIN AND DAPAGLIFLOZIN IN IMPROVING EJECTION FRACTION: A PROSPECTIVE OBSERVATIONAL COMPARISON OF CLINICAL OUTCOMES AND PATIENT REPORTED QUALITY OF LIFE

Background: SGLT2 inhibitors have transformed heart failure treatment, especially empagliflozin and dapagliflozin. Although both have proven cardiovascular benefits in clinical trials, there is little data comparing them in real-world settings. This study aims to address that by comparing their effects on heart functio...

C. Bhargava, M. Daisy, J. Sharon et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.